UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 5, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-55016 |
26-0690857 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
655 Montgomery Street, Suite 900
San Francisco, CA |
94111 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Items.
On May
5, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing that it has received
a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled,
“Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof.”
A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Amarantus Bioscience Holdings, Inc. Press Release, dated May
5, 2015. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: May 5, 2015 |
|
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
Exhibit 99.1
Amarantus Receives Notice of Allowance
for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
- Patent issuance will provide additional
IP protection for MANF protein therapy and cell therapy -
SAN FRANCISCO, CA, and
GENEVA, SWITZERLAND – May 5, 2015 - Amarantus BioScience Holdings,
Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic
and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of
Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled,
“Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof.” Upon issuance, the patent will
provide additional intellectual property protection for MANF
(mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover
compositions of matter and methods of use related to the Company’s proprietary manufacturing process for synthetic MANF
and its administration.
Native MANF is currently under development
for the treatment of orphan ocular indications, including retinitis pigmentosa (RP). Amarantus recently received orphan drug designation
for MANF for the treatment in RP in the United States and in Europe. In addition, MANF proteins have demonstrated proof-of-concept
in preclinical models to treat a wide range of conditions including retinal artery occlusion, glaucoma, macular degeneration, Parkinson’s
disease (PD), diabetes and ischemic heart disease, among others.
“This Notice of Allowance is another
important element in our intellectual property strategy that we believe will allow us to fully exploit the fundamental value of
the research and development ongoing for MANF, both internally and via our collaborations,” said Gerald E. Commissiong, President
& CEO of Amarantus. “MANF is being developed as a potential therapeutic intervention for orphan ocular diseases and other
chronic disorders for which few, if any, viable disease-modifying treatment options exist.”
“This important step further signals
the Company’s commitment to strengthening our industry-leading intellectual property portfolio surrounding MANF," said
John W. Commissiong, Ph.D., Amarantus CSO and co-discoverer of MANF. "We will continue to strengthen our robust intellectual
property estate to further protect and maintain our proprietary rights, which we believe will not only allow us to capitalize on
the known opportunities for MANF development, but will also further entrench Amarantus as the leading company for new collaborations
in light of emerging potential MANF applications.”
The USPTO issues a Notice of Allowance
after it makes a determination that a patent should be granted from a patent application.
About Mesencephalic-Astrocyte-derived
Neurotrophic Factor (MANF)
MANF
(mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring
protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease,
via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative
medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder
of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF,
a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was
discovered utilizing Amarantus' proprietary PhenoGuard™
Protein Discovery Engine.
MANF's lead indication is retinitis pigmentosa,
and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications
for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain
other rare orphan diseases currently under evaluation.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (AMBS) is
a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology
and regenerative medicine. AMBS’ Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer’s aggression, and owns intellectual
property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing
MANF-based products as treatments for brain and ophthalmic disorders. AMBS’ Diagnostics division owns the rights to MSPrecise®,
a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis
(RRMS) at first clinical presentation, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS
also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF’s discovery.
For further information please visit www.Amarantus.com,
or connect with the Company on Facebook, LinkedIn,
Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical
information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally
are identified by the words "believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from
the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include,
but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications
Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Source: Amarantus Bioscience Holdings,
Inc.
###
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024